DAEWOONG PHARMACEUTICAL
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HanAll Biopharma Reports Third Quarter 2021 Results 2021-10-28 21:00
CGBIO to introduce AI-empowered robotic intervention device, with clinical trials 2021-09-27 21:00
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics 2021-08-19 21:00
HanAll Biopharma Reports Second Quarter 2021 Results 2021-07-29 18:44
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial 2021-07-29 18:00
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes 2021-06-01 21:00
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test 2021-05-27 21:00
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF) shows promising result in early stage clinical test 2021-05-24 16:59
Daewoong showed improved performance both sales and earnings in Q1 2021-05-07 21:00
HanAll Biopharma Reports First Quarter 2021 Financial Results 2021-05-06 21:00
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study 2020-11-06 22:00
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide 2020-10-29 21:00
Daewoong Pharmaceutical's COVID-19 Treatment Candidate Also Highly Effective against Influenza Virus 2020-10-28 22:36
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic' 2020-10-27 21:00
Daewoong Pharmaceutical's new SGLT2 inhibitor for diabetes treatment demonstrates remarkable effect in phase 2 clinical trial 2020-09-29 15:00
Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment 2020-09-28 20:00
Daewoong Pharmaceutical Acquires Halal Certification for 'Easyef' through Daewoong Infion 2020-05-27 10:00
Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker 2020-05-11 08:00
Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells 2020-01-09 09:51
Daewoong Pharmaceutical Receives World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells through Indonesian Joint Venture, Daewoong Infion 2020-01-08 11:00
1 2 3 4